What is CinCor Pharma Earnings Power Value (EPV)?
As of Sep22, CinCor Pharma's earnings power value is $12.80. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
CinCor Pharma Earnings Power Value (EPV) Historical Data
The historical data trend for CinCor Pharma's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CinCor Pharma Earnings Power Value (EPV) Chart
|
CinCor Pharma Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
|
CinCor Pharma Quarterly Data
|
|
Dec19 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of CinCor Pharma's Earnings Power Value (EPV)
For the Biotechnology subindustry, CinCor Pharma's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CinCor Pharma's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CinCor Pharma's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where CinCor Pharma's Earnings Power Value (EPV) falls into.
CinCor Pharma Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
CinCor Pharma (CinCor Pharma) Business Description
Traded in Other Exchanges
N/A
Address
200 Clarendon Street, 6th Floor, Boston, MA, USA, 02116
CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.
Executives
| Sofinnova Management X-a, L.l.c. |
10 percent owner |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| James Healy |
director, 10 percent owner |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| Michael Wayne Kalb |
officer: EVP & Chief Financial Officer |
24 LUCILLE LANE, DIX HILLS NY 11746 |
| 5am Opportunities Ii (gp), Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISO CA 94107 |
| 5am Opportunities Ii, L.p. |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Partners Vi, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Partners Sas Sofinnova |
10 percent owner |
17 RUE DE SERENE, PARIS I0 75008 |
| Maha Katabi |
10 percent owner |
SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| Sofinnova Venture Partners X, L.p. |
10 percent owner |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| Sofinnova Management X, L.l.c. |
10 percent owner |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| General Atlantic Genpar (bermuda), L.p. |
10 percent owner |
C/O GENERAL ATLANTIC SERVICE COMPANY,LLC, 55 EAST 52ND ST. 32ND FLOOR, NEW YORK NY 10055 |
| General Atlantic, L.p. |
10 percent owner |
55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055 |
| Mason Freeman |
officer: EVP Clinical Development |
C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
| Mary Theresa Coelho |
officer: EVP CFO & Chief BD Officer |
52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
| Garidel Marc De |
director, officer: Chief Executive Officer |
C/O CINCOR PHARMA, INC., 200 CLARENDON STREET, 6TH FLOOR, BOSTON MA 02116 |
CinCor Pharma (CinCor Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CINC has been successfully added to your